O'Byrne Jason 4

What Happened

• Jason O'Byrne, Chief Financial Officer of Vir Biotechnology (VIR), reported a paired disposition and acquisition of 2,500 shares on 2026-03-20. Both entries show $0 consideration (price $0.00), indicating the shares were transferred rather than bought or sold for cash.
• The filing identifies the movement as an "other acquisition or disposition" (transaction code J) and includes a footnote stating the transfer was made without consideration for estate planning purposes. This is a non‑market transfer, not a typical purchase or sale.

Key Details

• Transaction date: 2026-03-20; Form 4 filed: 2026-03-23.
• Reported transactions: 2,500 shares disposed at $0.00 and 2,500 shares acquired at $0.00 (net effect: transfer).
• Footnotes: F1 — transfer without consideration for estate planning; F2 — shares are held in the O'Byrne Family Trust, of which the reporting person and spouse are Trustees.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Transaction code: J (other acquisition/disposition). The filing does not indicate a 10b5-1 plan or tax-withholding event.

Context

• Transfers into a family trust for estate planning are administrative and do not necessarily signal a buy/sell decision about the company’s prospects. Because the reporting person and spouse are trustees of the family trust, beneficial ownership often remains effectively unchanged even though legal title may move.
• This was not a market purchase or sale (no cash exchanged), so it should not be interpreted the same way as open-market insider buying or selling.